



DRUG DEVELOPMENT AND PERSONALIZED MEDICINE SOLUTIONS

Organoid Technology for Micro Tumor Environment Modeling

Contract Development and Manufacturing Services

Questions
about our
technologies?

Message us to
[contact
@radahaim.com](mailto:contact@radahaim.com)

At RadaHaim, we specialize in leveraging advanced organoid technologies to drive innovation in preclinical research and personalized medicine. Our team of experts is dedicated to supporting pharmaceutical companies, research institutes, and hospitals by providing end-to-end solutions—from organoid culturing to comprehensive screening services.

At the heart of our platform is our proprietary organoid culturing and sorting system. By integrating microfluidics, we can reliably culture and sort organoids in large volumes. This high-throughput approach not only speeds up research timelines but also ensures standardization and reproducibility, both critical factors in drug discovery and clinical applications.

Why Industry Leaders Choose Us:

- **Expertise & Innovation:** Our multidisciplinary team has extensive experience in stem cell biology, bioengineering, and translational research.
- **Partnership & Collaboration:** We work hand-in-hand with clients and partner organizations to accelerate drug discovery and patient care solutions.
- **Flexibility & Scalability:** Our technology platform is designed to adapt and scale based on the evolving requirements of pharmaceutical companies, hospitals, and research institutes.





Our Services

Contract Organoid Manufacturing

- **Customized Production:** We work closely with partners to adapt each organoid to their specific protocols and research needs.
- **Proprietary Mass Production & Sorting:** Our cutting-edge platform ensures high-throughput generation of organoids with uniform size and morphology.
- **Quality Control & Consistency:** Rigorous QC measures throughout the production process guarantee reproducible organoid batches suitable for downstream assays.

Organoid-Based Screening Services

- **FFPE Microarrays:** We provide organoid FFPE (Formalin-Fixed Paraffin-Embedded) microarrays that enable histopathological and immunohistochemical analyses.
- **Spatial Transcriptomics:** Through our partnership with a leading spatial transcriptomics provider, we offer detailed molecular profiling within the tissue context.
- **Toxicity & Efficacy Testing:** We help evaluate potential adverse effects and therapeutic benefits of drug candidates early in the R&D pipeline.

Patient-Specific Drug Screening

- **Personalized Approach:** We collaborate with hospitals to culture patient-derived organoids, enabling individualized treatment decisions.
- **Clinically Relevant Models:** By reflecting patient-specific genetic and pathological features, our organoid models improve predictive accuracy.
- **Customized Reporting:** Detailed screening results help inform clinicians on the most effective therapeutic strategies for their patients.

Key Benefits

- Rapid turnaround times for large-scale organoid production
- Consistent morphology and viability across batches
- Flexible manufacturing processes tailored to various tissue types
- Comprehensive insight into organoid-level drug responses
- Advanced imaging and molecular profiling options
- Streamlined data interpretation via integrative bioinformatics
- Accelerated discovery of optimal patient-specific therapies
- Reduction in trial-and-error treatments
- Enhanced clinical outcomes through evidence-based decisions

Headquarter:

RadaHaim Co., Ltd.
123, Unjung-ro
Floor 10
Bundang-gu
Seongnam-si
Gyeonggi-do
13461
Republic of Korea

As a trusted organoid & MPS solutions developer and provider, RadaHaim is committed to advancing organoid science to meet the growing needs of precision medicine and drug discovery. From custom manufacturing to integrated screening solutions, we offer the expertise and technology to bring your research and clinical applications to the next level.

For particularly tumor organoids, we provide services that include microfluidics-based mass production, immune cell co-culture, and gene-editing to accurately model the tumor microenvironment (TME). Our platform supports high-throughput drug screening and generates preclinical data to assist with IND submissions and collaborations with pharmaceutical companies.



contact@radahaim.com • www.radahaim.com

© 2025, RadaHaim Co., Ltd.